SCHEMBL10219836

SCHEMBL10219836

Cc1nc2cc(-c3nc4ccccc4o3)ccc2n1CC(=O)N1CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.51
▸ CREBBP Q92793 1/20 0.51
▸ GRIN2B Q13224 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TP53 P04637 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ MAPT P10636 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ FASN P49327 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687137 0.84 KDM4E (0.46) ALDH1A1MEN1HTTKMT2ACYP2C19
SCHEMBL2687887 0.81 LMNA (0.56) BRD4CREBBPGAA
SCHEMBL2688338 0.79 RAB9A (0.43) ALDH1A1MEN1HTTKMT2ATP53
SCHEMBL2686518 0.79 KDM4E (0.46) ALDH1A1MEN1KMT2ATP53CYP2C19
SCHEMBL2686294 0.79 BRD4 (0.46) BRD4ALDH1A1HTTMAPTKDM4E
SCHEMBL2687383 0.78 KDM4E (0.55) ALDH1A1MEN1HTTKMT2ATP53
SCHEMBL2688399 0.78 KDM4E (0.45) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL2688624 0.78 KMT2A (0.53) ALDH1A1MEN1HTTKMT2ATP53
SCHEMBL10219927 0.77 TLR9 (0.53) ALDH1A1HTTKDM4EHPGDHSD17B10
SCHEMBL2686062 0.77 BRD4 (0.48) BRD4ALDH1A1HTTTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 BRD4 2356/4885CREBBP 268/4885GRIN2B 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback